Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (1): 91-95.doi: 10.3969/j.issn.1000-6621.2021.01.017
• Review Articles • Previous Articles Next Articles
LI Guo, PANG Xian-qiong, XU Hua, JING Ming-yan, FAN Pang-shuang, CHEN Shao-ping()
Received:
2020-09-28
Online:
2021-01-10
Published:
2021-01-12
Contact:
CHEN Shao-ping
E-mail:chenshaoping836@163.com
LI Guo, PANG Xian-qiong, XU Hua, JING Ming-yan, FAN Pang-shuang, CHEN Shao-ping. Progress in diagnosis and treatment of latent tuberculosis infection[J]. Chinese Journal of Antituberculosis, 2021, 43(1): 91-95. doi: 10.3969/j.issn.1000-6621.2021.01.017
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.01.017
[1] | World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020. |
[2] |
Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 2016,13(10):e1002152. doi: 10.1371/journal.pmed.1002152.
doi: 10.1371/journal.pmed.1002152 URL pmid: 27780211 |
[3] |
Gao L, Lu W, Bai L, et al. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis, 2015,15(3):310-319. doi: 10.1016/S1473-3099(14)71085-0.
doi: 10.1016/S1473-3099(14)71085-0 URL pmid: 25681063 |
[4] | World Health Organization. WHO consolidated guidelines on tuberculosis module 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization, 2020. |
[5] | 高磊, 金奇. 关口前移: 结核潜伏感染及其控制. 中国防痨杂志, 2018,40(8):791-795. doi: 10.3969/j.issn.1000-6621.2018.08.003. |
[6] | 任哲雯, 成君, 徐彩红, 等. 肺结核患者密切接触者潜伏性结核感染预防性治疗研究进展. 中国防痨杂志, 2019,41(9):1021-1024. doi: 10.3969/j.issn.1000-6621.2019.09.020. |
[7] |
Stagg HR, Zenner D, Harris RJ, et al. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med, 2014,161(6):419-428. doi: 10.7326/M14-1019.
doi: 10.7326/M14-1019 URL |
[8] | 中华人民共和国国家卫生健康委员会. 中国结核病预防控制工作技术规范(2020年版). 国卫办疾控函〔2020〕279号. 2020-04-02. |
[9] | 中华人民共和国国家卫生和计划生育委员会. WS 196—2017结核病分类. 2017-11-09. |
[10] |
Zellweger JP, Sotgiu G, Corradi M, et al. The diagnosis of latent tuberculosis infection (LTBI): currently available tests, future developments, and perspectives to eliminate tuberculosis (TB). Med Lav, 2020,111(3):170-183. doi: 10.23749/mdl.v111i3.9983.
doi: 10.23749/mdl.v111i3.9983 URL pmid: 32624559 |
[11] | 蒋明娟, 刘思静, 汪川. 潜伏性结核感染诊断抗原研究进展. 现代预防医学, 2017,44(20):3837-3840. doi: CNKI:SUN:XDYF.0.2017-20-047. |
[12] | 中华医学会结核病学分会儿童结核病专业委员会, 国家儿童医学中心, 首都医科大学附属北京儿童医院, 等. 儿童结核分枝杆菌潜伏感染筛查和预防性治疗专家共识. 中华结核和呼吸杂志, 2020,43(4):345-349. doi: 10.3760/cma.j.cn112147-20200106-00006. |
[13] | 上海市防痨协会, 中国防痨协会青年理事会, 《中国防痨杂志》编辑委员会. 学校结核病疫情流行病学调查和现场处置专家共识. 中国防痨杂志, 2019,41(1):9-13. doi: 10.3969/j.issn.1000-6621.2019.01.004. |
[14] |
Tissot F, Zanetti G, Francioli P, et al. Influence of bacille Calmette-Guerin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis, 2005,40(2):211-217. doi: 10.1086/426434.
doi: 10.1086/426434 URL pmid: 15655737 |
[15] | 裴宁, 卢水华. WHO《潜伏性结核感染管理指南》要点解析及我国研究现状. 中国防痨杂志, 2015,37(7):736-739. doi: 10.3969/j.issn.1000-6621.2015.07.005. |
[16] |
Mulder C, Erkens C, Kouw P, et al. Tuberculin skin test reaction depends on type of purified protein derivative: implications for cut-off values. Int J Tuberc Lung Dis, 2019,23(12):1327-1334. doi: 10.5588/ijtld.18.0838.
doi: 10.5588/ijtld.18.0838 URL pmid: 31931917 |
[17] | 卢鹏, 成君, 路希维, 等. 科学开展预防性治疗加速遏制结核病进程. 中国防痨杂志, 2020,42(4):316-321. doi: 10.3969/j.issn.1000-6621.2020.04.004. |
[18] |
van Zyl-Smit RN, Pai M, Peprah K, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med, 2009,180(1):49-58. doi: 10.1164/rccm.200811-1704OC.
doi: 10.1164/rccm.200811-1704OC URL pmid: 19342414 |
[19] |
Kahwati LC, Feltner C, Halpern M, et al. Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 2016,316(9):970-983. doi: 10.1001/jama.2016.10357.
doi: 10.1001/jama.2016.10357 URL pmid: 27599332 |
[20] |
Sun L, Xiao J, Miao Q, et al. Interferon gamma release assay in diagnosis of pediatric tuberculosis: a meta-analysis. FEMS Immunol Med Microbiol, 2011,63(2):165-173. doi: 10.1111/j.1574-695X.2011.00838.x.
doi: 10.1111/j.1574-695X.2011.00838.x URL pmid: 22077219 |
[21] |
Gao L, Li X, Liu J, et al. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis, 2017,17(10):1053-1061. doi: 10.1016/S1473-3099(17)30402-4.
doi: 10.1016/S1473-3099(17)30402-4 URL pmid: 28716677 |
[22] |
Li H, Xin H, Qian S, et al. Testing of tuberculosis infection among Chinese adolescents born after terminating the Bacillus Calmette-Guérin booster vaccination: subgroup analysis of a population-based cross-sectional study. Front Med, 2017,11(4):528-535. doi: 10.1007/s11684-017-0573-0.
doi: 10.1007/s11684-017-0573-0 URL pmid: 29101754 |
[23] |
Abubakar I, Lalvani A, Southern J, et al. Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study. Health Technol Assess, 2018,22(56):1-96. doi: 10.3310/hta22560.
doi: 10.3310/hta22560 URL pmid: 30334521 |
[24] | 高磊, 权竹声, 成君, 等. 结核分枝杆菌感染检测两步法在学校结核病控制工作中的应用探讨. 中华预防医学杂志, 2020,54(4):385-391. doi: 10.3760/cma.j.cn112150-20191204-00909. |
[25] | 中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会, 《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识. 中国防痨杂志, 2020,42(8):761-768. doi: 10.3969/j.issn.1000-6621.2020.08.001. |
[26] |
Li F, Xu M, Qin C, et al. Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial. Clin Microbiol Infect, 2016, 22(10): 889.e9-889.e16. doi: 10.1016/j.cmi.2016.07.015.
doi: 10.1016/j.cmi.2016.07.015 URL |
[27] | 李果. 2020年WHO综合指南更新解读: 结核预防性治疗. 医师在线, 2020,10(15):22-23. |
[28] |
Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med, 2011,365(1):11-20. doi: 10.1056/NEJMoa1005136.
doi: 10.1056/NEJMoa1005136 URL pmid: 21732833 |
[29] | Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev, 2010, 2010 (1): CD000171. doi: 10.1002/14651858.CD000171.pub3. |
[30] |
Golub JE, Cohn S, Saraceni V, et al. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis, 2015,60(4):639-645. doi: 10.1093/cid/ciu849.
doi: 10.1093/cid/ciu849 URL pmid: 25365974 |
[31] | 程馨禾, 边赛男, 张峣, 等. 潜伏性结核分枝杆菌感染的预防性治疗. 中华实验和临床感染病杂志(电子版), 2016,10(2):129-135. doi: 10.3877/cma.j.issn.1674-1358.2016.02.001. |
[32] |
Zenner D, Beer N, Harris RJ, et al. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. Ann Intern Med, 2017,167(4):248-255. doi: 10.7326/M17-0609.
doi: 10.7326/M17-0609 URL pmid: 28761946 |
[33] |
Galli L, Lancella L, Tersigni C, et al. Pediatric Tuberculosis in Italian Children: Epidemiological and Clinical Data from the Italian Register of Pediatric Tuberculosis. Int J Mol Sci, 2016,17(6):960. doi: 10.3390/ijms17060960.
doi: 10.3390/ijms17060960 URL |
[34] | 魏建华, 黄兴玲, 郭涛. 264例潜伏性结核感染两联抗结核药物不良反应临床分析. 宁夏医学杂志, 2018,40(2):171-172. doi: 10.13621/j.1001-5949.2018.02.0171. |
[35] |
Sterling TR, Scott NA, Miro JM, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS, 2016,30(10):1607-1615. doi: 10.1097/QAD.0000000000001098.
doi: 10.1097/QAD.0000000000001098 URL pmid: 27243774 |
[36] | 杨清銮, 阮巧玲, 张文宏. HIV感染人群潜伏性结核感染筛查与预防性治疗. 临床内科杂志, 2019,36(11):729-732. doi: 10.3969/j.issn.1001-9057.2019.11.004. |
[37] |
Sun HY, Huang YW, Huang WC, et al. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. Tuberculosis (Edinb), 2018,111:121-126. doi: 10.1016/j.tube.2018.05.013.
doi: 10.1016/j.tube.2018.05.013 URL |
[38] | 任哲雯, 张国龙, 龚德华, 等. 结核潜伏感染者对12周预防性治疗方案的接受意愿研究. 中国防痨杂志, 2020,42(5):503-509. doi: 10.3969/j.issn.1000-6621.2020.05.016. |
[39] |
Gao L, Zhang H, Xin H, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J, 2018,52(6):1801470. doi: 10.1183/13993003.01470-2018.
doi: 10.1183/13993003.01470-2018 URL pmid: 30361241 |
[40] |
Swindells S, Ramchandani R, Gupta A, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med, 2019,380(11):1001-1011. doi: 10.1056/NEJMoa1806808.
doi: 10.1056/NEJMoa1806808 URL pmid: 30865794 |
[41] |
Menzies D, Adjobimey M, Ruslami R, et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med, 2018,379(5):440-453. doi: 10.1056/NEJMoa1714283.
doi: 10.1056/NEJMoa1714283 URL pmid: 30067931 |
[42] | 姚晶, 顾凯侃, 李智红, 等. 结核潜伏感染的研究现况概述. 结核与肺部疾病杂志, 2020,1(1):82-88. doi: 10.3969/j.issn.2096-8493.2020.01.017. |
[43] |
Cui X, Gao L, Cao B. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries. Int J Infect Dis, 2020,92S:S37-S40. doi: 10.1016/j.ijid.2020.02.034.
doi: 10.1016/j.ijid.2020.02.034 URL pmid: 32114201 |
[1] | CUI Xiao-jing, WEI Dong, WANG Chun-lei, CAO Bin. Value of molecular diagnosis and liquid culture methods in improving the pathogenic diagnosis of pulmonary tuberculosis in general hospitals [J]. Chinese Journal of Antituberculosis, 2021, 43(2): 143-146. |
[2] | MI Jie, XUE Yong, BAI Xue-juan, WU Xue-qiong. The research progress of lymphocyte subsets detection in diagnosis and treatment of tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(2): 178-185. |
[3] | Chinese Antituberculosis Association. Tuberculosis research progress in 2020 [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 6-11. |
[4] | LIU Jian-xiong, DU Yu-hua, SHEN Hong-cheng, ZHANG Guang-chuan, WU Gui-feng, LAI Keng, LEI Yu, LI Tie-gang. Influencing factors of pulmonary tuberculosis diagnosis delay in Guangzhou, 2008—2018 [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 80-86. |
[5] | ZHOU Lin, LIU Er-yong, MENG Qing-lin, CHEN Ming-ting, ZHOU Xin-hua, GAO Wei-wei, LIN Ming-gui, XIE Ru-ming. Evaluation of the quality of pulmonary tuberculosis diagnosis after the implementation of the newly revised WS 288-2017 Diagnosis for pulmonary tuberculosis standards [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 910-915. |
[6] | LIU Er-yong, WANG Qian, ZHOU Lin, ZHANG Guo-qin, ZHANG Xiu-lei, MA Yong-cheng, YANG Shu-min, WANG Cui, MENG Qing-lin, CHEN Ming-ting, LIN Ming-gui, TU De-hua.. Analysis of diagnostic quality of pulmonary tuberculosis with negative etiology in some areas of China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 916-920. |
[7] | WANG Qian, ZHOU Lin, LIU Er-yong, ZHAO Yan-lin, LI Tao, CHEN Ming-ting, YANG Li-jia, WANG Jia.. A survey on the diagnostic ability of tuberculosis in the county-level medical institutions in China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 926-930. |
[8] | LIANG Rui-yun, FANG Wei-jun, REN Hui-li, LI Hui-ru, ZHANG Hui. Study on CT manifestations of non-tuberculous mycobacterium pulmonary disease patients with and without diabetes mellitus [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 962-967. |
[9] | NAN Hai, ZHANG Yun, YANG Xin-ting, DUAN Hong-fei. Meta-analysis on the diagnostic value of GeneXpert MTB/RIF for bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 973-980. |
[10] | Chinese Antituberculosis Association, Schools and Children Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of the recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 761-768. |
[11] | ZHAO Ai-hua, KANG Wan-li, WANG Guo-zhi, GAO Zheng-lun, DU Wei-xin, LU Jin-biao, SHEN Xiao-bing, SU Cheng, XU Miao, ZHENG Su-hua. Screening for latent tuberculosis infection and identification of BCG vaccination by recombinant Mycobacterium tuberculosis 11 kDa [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 821-825. |
[12] | CHEN Feng-fang, MA Jun, HUANG Jin, YIN Hong-yun, SHA Wei, YANG Guang-hong, FENG Yong-hong. Preliminary study on establishing the diagnostic model for smear negative tuberculosis and stage Ⅰ/Ⅱ sarcoidosis with hilar/mediastinal lymphadenopathy and positive T-SPOT.TB results [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 832-837. |
[13] | SUN Qing, HUANG Hai-rong, WANG Gui-rong. In vitro activities and drug resistance mechanisms of bedaquiline, clofazimine and delamanid against common pathogenic non-tuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 880-884. |
[14] | ZENG Yi, GAO Wei-wei, GONG Su-gang, HOU Dai-lun. Analysis on clinical diagnosis and treatment of two cases with mediastinal fibrosis caused by tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 747-751. |
[15] | SHEN Xin, SHA Wei, LIU Jian-jun. Impact of coronavirus disease 2019 (COVID-19) on tuberculosis control and countermeasures in China [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 544-548. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||